Advertisement

Neurotoxicity Research

, Volume 33, Issue 3, pp 621–633 | Cite as

Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study

  • Buranee Kanchanatawan
  • Sookjaroen Tangwongchai
  • Atapol Sughondhabhirom
  • Siriluck Suppapitiporn
  • Solaphat Hemrunrojn
  • André F. Carvalho
  • Michael Maes
ORIGINAL ARTICLE

Abstract

Activation of immune-inflammatory and oxidative-nitrosative (IO&NS) stress pathways plays a role in major depression (MDD). Evidence suggests that curcumin (500–1000 mg/day), a polyphenol with strong anti-IO&NS properties, may have efficacy either as monotherapy or as an adjunctive treatment for depression. Further controlled trials with extended treatment periods (> 8 weeks) and higher curcumin doses are warranted. This 12-week study was carried out to examine the effects of adjunctive curcumin for the treatment of MDD. In this double-blind, placebo-controlled trial, 65 participants with MDD were randomized to receive either adjunctive curcumin (increasing dose from 500 to 1500 mg/day) or placebo for 12 weeks. Four weeks after the active treatment phase, a follow-up visit was conducted at week 16. Assessments of the primary, i.e., the Montgomery-Asberg Depression Rating Scale (MADRS), and secondary, i.e., the Hamilton Anxiety Rating Scale (HAM-A), outcome measures were rated at baseline and 2, 4, 8, 12, and 16 weeks later. Curcumin was more efficacious than placebo in improving MADRS scores with significant differences between curcumin and placebo emerging at weeks 12 and 16. The effects of curcumin were more pronounced in males compared to females. There were no statistically significant treatment-emerging adverse effects and no significant effects of curcumin on blood chemistry and ECG measurements. Adjunctive curcumin has significant antidepressant effects in participants with MDD as evidenced by significant benefits occurring 12 and 16 weeks after treatment initiation. Curcumin administration was safe and well-tolerated even when combined with antidepressants. Future trials should include treatment-by-sex interactions to examine putative antidepressant effects of immune-modifying compounds.

Keywords

Depression Oxidative and nitrosative stress Immune Inflammation 

Notes

Acknowledgements

This research has been supported by the Agricultural Research Developmental Agency (ARDA), Bangkok, Thailand. The funding agency played no role in dada reporting. The authors would like to thank Supaksorn Thika (ST) for her valuable help completing the rating scales.

Author’s Contributions

All the contributing authors have participated in the manuscript. BK and MM designed the study. BK recruited patients and completed diagnostic interviews. All authors contributed to interpretation of the data and writing of the manuscript. MM carried out the statistical analyses.

Compliance with Ethical Standards

Conflict of Interest

The authors have no conflict of interest with any commercial or other association in connection with the submitted article.

References

  1. Al-Karawi D, Al Mamoori DA, Tayyar Y (2016) The role of curcumin administration in patients with major depressive disorder: Mini meta-analysis of clinical trials. Phytother Res 30(2):175–183.  https://doi.org/10.1002/ptr.5524 CrossRefPubMedGoogle Scholar
  2. Anderson G, Maes M (2014) TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol Disord Drug Targets 13(1):137–149.  https://doi.org/10.2174/18715273113129990082 CrossRefPubMedGoogle Scholar
  3. Banji D, Banji OJ, Dasaroju S, Kranthi KC (2013) Curcumin and piperine abrogate lipid and protein oxidation induced by D-galactose in rat brain. Brain Res 1515:1–11.  https://doi.org/10.1016/j.brainres.2013.03.023 CrossRefPubMedGoogle Scholar
  4. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010) Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303(12):1180–1187.  https://doi.org/10.1001/jama.2010.310 CrossRefPubMedGoogle Scholar
  5. Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64(1):43–51.  https://doi.org/10.1016/S0165-0327(00)00199-3 CrossRefPubMedGoogle Scholar
  6. Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M (2014) Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 159:23–30.  https://doi.org/10.1016/j.jad.2014.02.018 CrossRefPubMedGoogle Scholar
  7. Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 83(2):70–88.  https://doi.org/10.1159/000357500 CrossRefPubMedGoogle Scholar
  8. Ciftci G, Aksoy A, Cenesiz S, Sogut MU, Yarim GF, Nisbet C, Guvenc D, Ertekin A (2015) Therapeutic role of curcumin in oxidative DNA damage caused by formaldehyde. Microsc Res Tech 78(5):391–395.  https://doi.org/10.1002/jemt.22485 CrossRefPubMedGoogle Scholar
  9. de Melo LGP, Nunes SOV, Anderson G, Vargas HO, Barbosa DS, Galecki P, Carvalho AF, Maes M (2017) Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 78:34–50.  https://doi.org/10.1016/j.pnpbp.2017.04.027 CrossRefGoogle Scholar
  10. de Oliveira MR, Jardim FR, Setzer WN, Nabavi SM, Nabavi SF (2016) Curcumin, mitochondrial biogenesis, and mitophagy: exploring recent data and indicating future needs. Biotechnol Adv 34(5):813–826.  https://doi.org/10.1016/j.biotechadv.2016.04.004 CrossRefPubMedGoogle Scholar
  11. Esmaily H, Sahebkar A, Iranshahi M, Ganjali S, Mohammadi A, Ferns G, Ghayour-Mobarhan M (2015) An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 21(5):332–338.  https://doi.org/10.1007/s11655-015-2160-z CrossRefPubMedGoogle Scholar
  12. Farooqui AA (2016) Therapeutic potentials of curcumin for Alzheimer disease. Springer, Berlin.  https://doi.org/10.1007/978-3-319-15889-1 CrossRefGoogle Scholar
  13. Gałecki P, Gałecka E, Maes M, Chamielec M, Orzechowska A, Bobińska K, Lewiński A, Szemraj J (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 138(3):360–366.  https://doi.org/10.1016/j.jad.2012.01.016 CrossRefPubMedGoogle Scholar
  14. Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A (2017) Effects of curcumin on HDL functionality. Pharmacol Res 119:208–218.  https://doi.org/10.1016/j.phrs.2017.02.008 CrossRefPubMedGoogle Scholar
  15. Ghandadi M, Sahebkar A (2017) Curcumin: an effective inhibitor of interleukin-6. Curr Pharm Des 23(6):921–931.  https://doi.org/10.2174/1381612822666161006151605 CrossRefPubMedGoogle Scholar
  16. Gomes C, Martinho FC, Barbosa DS, Antunes LS, Póvoa HCC, Baltus THL, Morelli NR, Vargas HO, Nunes SOV, Anderson G, Maes M (2017) Increased root canal endotoxin levels are associated with chronic apical periodontitis, increased oxidative and nitrosative stress, major depression, severity of depression, and a lowered quality of life. Mol Neurobiol.  https://doi.org/10.1007/s12035-017-0545-z
  17. González-Reyes S, Guzmán-Beltrán S, Medina-Campos ON, Pedraza-Chaverri J (2013) Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxidative Med Cell 2013:801418Google Scholar
  18. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32(1):50–55.  https://doi.org/10.1111/j.2044-8341.1959.tb00467.x CrossRefPubMedGoogle Scholar
  19. Hewlings SJ, Kalman DS (2017) Curcumin: a review of Its’ effects on human health. Foods 6(10).  https://doi.org/10.3390/foods6100092
  20. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71(2):171–186.  https://doi.org/10.1097/PSY.0b013e3181907c1b CrossRefPubMedGoogle Scholar
  21. Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, Lee CM, Chun SH, Yoon MS, Kim GT, Ryu SW, Kim JS, Shin YK, Lee WS, Shin HK, Lee JD, Park YM (2009) Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem 284(6):3700–3708.  https://doi.org/10.1074/jbc.M807328200 CrossRefPubMedGoogle Scholar
  22. Jurrmann N, Brigelius-Flohé R, Böl GF (2005) Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J Nutr 135(8):1859–1864CrossRefPubMedGoogle Scholar
  23. Kaufmann FN, Gazal M, Bastos CR, Kaster MP, Ghisleni G (2016) Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Eur J Pharmacol 784:192–198.  https://doi.org/10.1016/j.ejphar.2016.05.026 CrossRefPubMedGoogle Scholar
  24. Kittirathanapaiboon P, Khamwongpin M (2005) The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.) Thai version. Suanprung Hospital, Department of Mental HealthGoogle Scholar
  25. Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71(12):1381–1391.  https://doi.org/10.1001/jamapsychiatry.2014.1611 CrossRefPubMedGoogle Scholar
  26. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF (2017a) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135(5):373–387.  https://doi.org/10.1111/acps.12698 CrossRefPubMedGoogle Scholar
  27. Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, de Andrade NQ, Morris G, Fernandes BS, Brunoni AR, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF (2017b) Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol.  https://doi.org/10.1007/s12035-017-0632-1
  28. Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36(2):764–785.  https://doi.org/10.1016/j.neubiorev.2011.12.005 CrossRefPubMedGoogle Scholar
  29. Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139(3):230–239.  https://doi.org/10.1016/j.jad.2011.08.003 CrossRefPubMedGoogle Scholar
  30. Liu T, Zhong S, Liao X, Chen J, He T, Lai S, Jia Y (2015) A meta-analysis of oxidative stress markers in depression. PLoS One 10(10):e0138904.  https://doi.org/10.1371/journal.pone.0138904 CrossRefPubMedPubMedCentralGoogle Scholar
  31. Lopresti AL (2017) Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol 31(3):287–302.  https://doi.org/10.1177/0269881116686883 CrossRefPubMedGoogle Scholar
  32. Lopresti AL, Drummond PD (2017) Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: a randomised, double-blind, placebo-controlled study. J Affect Disord 207:188–196.  https://doi.org/10.1016/j.jad.2016.09.047 CrossRefPubMedGoogle Scholar
  33. Lopresti AL, Hood SD, Drummond PD (2012) Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 26(12):1512–1524.  https://doi.org/10.1177/0269881112458732 CrossRefPubMedGoogle Scholar
  34. Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD (2014) Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord 167:368–375.  https://doi.org/10.1016/j.jad.2014.06.001 CrossRefPubMedGoogle Scholar
  35. Lopresti AL, Maes M, Meddens MJ, Maker GL, Arnoldussen E, Drummond PD (2015) Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur Neuropsychopharmacol 25(1):38–50.  https://doi.org/10.1016/j.euroneuro.2014.11.015 CrossRefPubMedGoogle Scholar
  36. Maes M (1995) Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry 19(1):11–38.  https://doi.org/10.1016/0278-5846(94)00101-M CrossRefGoogle Scholar
  37. Maes M (2005) Van Freud tot omega-3, 2005. Standaard Uitgeverij, Antwerpen, 240 pagina's, 9789002214813Google Scholar
  38. Maes M (2008) The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29(3):287–291PubMedGoogle Scholar
  39. Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J (1990) Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 24(3):115–120.  https://doi.org/10.1159/000119472 CrossRefPubMedGoogle Scholar
  40. Maes M, Delanghe J, Meltzer HY, Scharpé S, D'Hondt P, Cosyns P (1994) Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr Scand 90(4):252–258.  https://doi.org/10.1111/j.1600-0447.1994.tb01589.x CrossRefPubMedGoogle Scholar
  41. Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, Demedts P, Wauters A, Meltzer HY (1997) Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand 95(3):212–221CrossRefPubMedGoogle Scholar
  42. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999) Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85(3):275–291.  https://doi.org/10.1016/S0165-1781(99)00014-1 CrossRefPubMedGoogle Scholar
  43. Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000) Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 58(3):241–246.  https://doi.org/10.1016/S0165-0327(99)00121-4 CrossRefPubMedGoogle Scholar
  44. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27–53.  https://doi.org/10.1007/s11011-008-9118-1 CrossRefPubMedGoogle Scholar
  45. Maes M, Galecki P, Chang YS, Berk M (2011a) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):676–692.  https://doi.org/10.1016/j.pnpbp.2010.05.004 CrossRefGoogle Scholar
  46. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011b) The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):702–721CrossRefGoogle Scholar
  47. Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011c) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418.  https://doi.org/10.1016/j.jad.2011.08.023 CrossRefPubMedGoogle Scholar
  48. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20(3):127–150.  https://doi.org/10.1007/s10787-011-0111-7 CrossRefPubMedGoogle Scholar
  49. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Brit J Psychiatry 134(4):382–389.  https://doi.org/10.1192/bjp.134.4.382 CrossRefGoogle Scholar
  50. Moylan S, Maes M, Wray NR, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18(5):595–606.  https://doi.org/10.1038/mp.2012.33 CrossRefPubMedGoogle Scholar
  51. Ng QX, Koh SSH, Chan HW, Ho CYX (2017) Clinical use of curcumin in depression: a meta-analysis. J Am Med Dir Assoc 18(6):503–508.  https://doi.org/10.1016/j.jamda.2016.12.071 CrossRefPubMedGoogle Scholar
  52. Panahi Y, Badeli R, Karami GR, Sahebkar A (2015) Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29(1):17–21.  https://doi.org/10.1002/ptr.5211 CrossRefPubMedGoogle Scholar
  53. Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 43(5):315–319.  https://doi.org/10.1016/S0006-3223(97)00206-0 CrossRefPubMedGoogle Scholar
  54. Psaty BM, Rennie D (2003) Stopping medical research to save money: a broken pact with researchers and patients. JAMA 289(16):2128–2131.  https://doi.org/10.1001/jama.289.16.2128 CrossRefPubMedGoogle Scholar
  55. Rizavi HS, Ren X, Zhang H, Bhaumik R, Pandey GN (2016) Abnormal gene expression of proinflammatory cytokines and their membrane-bound receptors in the lymphocytes of depressed patients. Psychiatry Res 240:314–320.  https://doi.org/10.1016/j.psychres.2016.04.049 CrossRefPubMedPubMedCentralGoogle Scholar
  56. Roomruangwong C, Barbosa DS, Matsumoto AK, Nogueira AS, Kanchanatawan B, Sirivichayakul S, Carvalho AF, Duleu S, Geffard M, Moreira EG, Maes M (2017) Activated neuro-oxidative and neuro-nitrosative pathways at the end of term are associated with inflammation and physio-somatic and depression symptoms, while predicting outcome characteristics in mother and baby. J Affect Disord 223:49–58.  https://doi.org/10.1016/j.jad.2017.07.002 CrossRefPubMedGoogle Scholar
  57. Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB (2014) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res 28(4):579–585.  https://doi.org/10.1002/ptr.5025 CrossRefPubMedGoogle Scholar
  58. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–23PubMedGoogle Scholar
  59. Slyepchenko A, Maes M, Köhler CA, Anderson G, Quevedo J, Alves GS, Berk M, Fernandes BS, Carvalho AF (2016) T helper 17 cells may drive neuroprogression in major depressive disorder: proposal of an integrative model. Neurosci Biobehav Rev 64:83–100.  https://doi.org/10.1016/j.neubiorev.2016.02.002 CrossRefPubMedGoogle Scholar
  60. Sobczak S, Honig A, Christophe A, Maes M, Helsdingen RW, De Vriese SA, Riedel WJ (2004) Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol Med 34(1):103–112.  https://doi.org/10.1017/S0033291703001090 CrossRefPubMedGoogle Scholar
  61. Soto-Urquieta MG, López-Briones S, Pérez-Vázquez V, Saavedra-Molina A, González-Hernández GA, Ramírez-Emiliano J (2014) Curcumin restores mitochondrial functions and decreases lipid peroxidation in liver and kidneys of diabetic db/db mice. Biol Res 47(1):74.  https://doi.org/10.1186/0717-6287-47-74 CrossRefPubMedPubMedCentralGoogle Scholar
  62. Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N (2006) Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 91(1):63–70.  https://doi.org/10.1016/j.jad.2005.12.010 CrossRefPubMedGoogle Scholar
  63. Valkanova V, Ebmeier KP, Allan CL (2013) CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 150(3):736–744.  https://doi.org/10.1016/j.jad.2013.06.004 CrossRefPubMedGoogle Scholar
  64. Vargas HO, Nunes SO, Pizzo de Castro M, Bortolasci CC, Sabbatini Barbosa D, Kaminami Morimoto H, Venugopal K, Dodd S, Maes M, Berk M (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 150(3):923–930.  https://doi.org/10.1016/j.jad.2013.05.016 CrossRefPubMedGoogle Scholar
  65. Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL (2015) Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 35(4):406–410PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry, Faculty of MedicineChulalongkorn UniversityBangkokThailand
  2. 2.Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of MedicineFederal University of CearáFortalezaBrazil
  3. 3.Department of PsychiatryMedical University PlovdivPlovdivBulgaria
  4. 4.IMPACT Strategic Research Center, Barwon HealthDeakin UniversityGeelongAustralia

Personalised recommendations